« Previous
Next »
Titles
- Gaps in coverage among people with pre-existing conditions1
- General principles for evaluating the abuse deterrence of generic solid oral opioid drug products1
- Generic Drug User Fee Amendments of 2012: questions and answers related to self-identification of facilities, review of generic drug submissions, and inspections and compliance1
- Generic drug development: stakeholders’ views of risk evaluation and mitigation strategies differ : report to the Chairman, Committee on Energy and Commerce, House of Representatives1
- Generic drug user fees: application review times declined, but FDA should develop a plan for administering its unobligated user fees : report to the Chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate1
- Generic drugs: FDA should make public its plans to issue and revise guidance on nonbiological complex drugs : report to Congressional requesters1
- Geriatrician roles and the value of geriatrics in an evolving healthcare system1
- Getting ready for health reform 2020: what past presidential campaigns can teach us1
- Getting to the root of high prescription drug prices: drivers and potential solutions1
- Governor's proposed budgets for FY 2018: focus on Medicaid and other health priorities1
- Governors' proposed budgets for FY 2019: focus on Medicaid and other health priorities1
- Growing community health centers across New York State1
- Guide to impact investing1
- Gulf War illness: additional actions needed to improve VA's claims process : testimony before the Subcommittees on Oversight and Investigations and Disability Assistance and Memorial Affairs, Committee on Veterans' Affairs, House of Representatives1
- Gulf War illness: improvements needed for VA to better understand, process, and communicate decisions on claims : report to Congressional requesters1